BackEpigenomics AG Overview

Epigenomics AG Current Assets

Track Epigenomics AG's current assets ($17M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$16.89M
↓ 35.09% YoYΔ $-9.13M vs prior year quarter

Peer trimmed avg / median

Loading

Epigenomics AG Current Assets History

Loading

Epigenomics AG vs. peers: Current Assets Comparison

Loading

Epigenomics AG Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Epigenomics AG (ECX.DE) FAQ

As of the most recent data (September 2022), ECX.DE shows a current assets of $17M. That compares with $26M in the prior-year period — down 35.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ECX.DE's current assets is now $17M (was $26M) — a 35.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Epigenomics AG is outperforming or lagging.

Tracking ECX.DE's current assets over time shows whether Epigenomics AG is scaling, shrinking, or reshaping that part of the business. The current reading is $17M That compares with $26M in the prior-year period — down 35.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current assets page, Stockcircle has Epigenomics AG's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current assets (currently $17M) with ownership activity and broader fundamentals.